Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a
clinical-stage biopharmaceutical company focused on improving the
lives of patients with genetically defined rare diseases, today
announced multiple presentations at the 2020 American Academy of
Neurology (AAN) Science Highlights Virtual Platform. AAN’s
annual meeting was cancelled due to COVID-19 and the virtual
platform allows for all accepted oral and poster presentations to
be presented. The materials linked below will be
available for approximately 10 months.
“We are pleased by the breadth of losmapimod data selected for
presentation, which highlights the progress we’ve made to develop a
treatment for patients with facioscapulohumeral muscular dystrophy
(FSHD) and our approach to treating the root cause of genetically
defined rare diseases,” said Diego Cadavid, M.D., Fulcrum’s
senior vice president, clinical development. “In particular, we
have identified a set of stable DUX4-regulated gene transcripts
that provide a pharmacodynamic biomarker endpoint to measure the
treatment effect of losmapimod in FSHD. Additionally, in
collaboration with AMRA Medical, we have created a standardized
whole-body magnetic resonance imaging (MRI) protocol to evaluate
skeletal muscle composition in FSHD patients. I would like to
thank the patients and their families who have participated in our
trials, and who inspire us every day.”
2020 AAN Virtual Platform Presentation and Poster
Details
Phase 1 Clinical Trial of Losmapimod in
Facioscapulohumeral Muscular Dystrophy (FSHD): Safety,
Tolerability, and Target Engagement
https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2192
Design of a Phase 2, Randomized, Double-Blind,
Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy
and Safety of Losmapimod in Treating Subjects with
Facioscapulohumeral Muscular Dystrophy (FSHD): ReDUX4
https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2193
Development of an Optimized Timed Up and Go
(oTUG) for Measurement of Changes in Mobility Impairment in
Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical
Trials
https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/1638
A Biomarker of DUX4 Activity to Evaluate losmapimod
Treatment Effect in FSHD Phase 2 Trials
https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2196
An In-Home Study of Facioscapulohumeral Muscular
Dystrophy (FSHD) Patients using Contactless Wireless Sensing and
Machine Learning
https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/1721
Development and Evaluation of a Whole-body MRI Imaging
Protocol and Analysis Algorithms to Measure Changes in Skeletal
Muscle in FSHD
https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2176
About FSHDFSHD is characterized by progressive
skeletal muscle loss that initially causes weakness in muscles in
the face, shoulders, arms, and trunk, and progresses to weakness
throughout the lower body. Skeletal muscle weakness results in
significant physical limitations, including an inability to smile
and difficulty using arms for activities, with many patients
ultimately becoming dependent upon the use of a wheelchair for
daily mobility.
FSHD is caused by mis-expression of DUX4 in skeletal muscle,
resulting in the presence of DUX4 proteins that are toxic to muscle
tissue. Normally, DUX4-driven gene expression is limited to early
embryonic development, after which time the DUX4 gene is silenced.
In people with FSHD, the DUX4 gene is turned “on” as a result of a
genetic mutation. The result is death of muscle and its replacement
by fat, leading to skeletal muscle weakness and progressive
disability. There are no approved therapies for FSHD, one of the
most common forms of muscular dystrophy, with an estimated patient
population of 16,000 to 38,000 in the United States alone.
About Losmapimod Losmapimod is a selective
p38α/β mitogen activated protein kinase (MAPK) inhibitor that was
exclusively in-licensed from GSK by Fulcrum Therapeutics following
Fulcrum’s discovery of the role of p38α/β inhibitors in the
reduction of DUX4 expression and an extensive review of known
compounds. Utilizing its internal product engine, Fulcrum
discovered that inhibition of p38α/β reduced expression of the DUX4
gene in muscle cells derived from patients with FSHD. Although
losmapimod has never previously been explored in muscular
dystrophies, it has been evaluated in more than 3,500 subjects in
clinical trials across multiple other indications, including in
several Phase 2 trials and a Phase 3 trial. No safety signals were
attributed to losmapimod in any of these trials. Fulcrum is
currently conducting Phase 2 trials investigating the safety,
tolerability, and efficacy of losmapimod to treat the root cause of
FSHD.
About Fulcrum Therapeutics Fulcrum Therapeutics
is a clinical-stage biopharmaceutical company focused on improving
the lives of patients with genetically defined rare diseases in
areas of high unmet medical need. Fulcrum’s proprietary product
engine identifies drug targets which can modulate gene expression
to treat the known root cause of gene mis-expression. The company
has advanced losmapimod to Phase 2 clinical development for the
treatment of facioscapulohumeral muscular dystrophy (FSHD) and has
completed extensive pre-clinical research for FTX-6058 for the
treatment of sickle cell disease and beta-thalassemia.
Please visit www.fulcrumtx.com.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties, including statements regarding
the development status of the Company’s product candidates. All
statements, other than statements of historical facts, contained in
this press release, including statements regarding the Company’s
strategy, future operations, future financial position, prospects,
plans and objectives of management, are forward-looking statements.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in,
or implied by, such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks associated
with Fulcrum’s ability to obtain and maintain necessary approvals
from the FDA and other regulatory authorities; continue to advance
its product candidates in clinical trials; replicate in later
clinical trials positive results found in preclinical studies and
early-stage clinical trials of losmapimod and its other product
candidates; advance the development of its product candidates under
the timelines it anticipates in current and future clinical trials;
obtain, maintain or protect intellectual property rights related to
its product candidates; manage expenses; and raise the substantial
additional capital needed to achieve its business objectives. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause the Company’s actual results to
differ from those contained in the forward-looking statements, see
the “Risk Factors” section, as well as discussions of potential
risks, uncertainties and other important factors, in the Company’s
most recent filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date hereof and
should not be relied upon as representing the Company’s views as of
any date subsequent to the date hereof. The Company anticipates
that subsequent events and developments will cause the Company’s
views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so.
Contact:
Investors: Christi Waarich Director, Investor Relations and
Corporate
Communications617-651-8664cwaarich@fulcrumtx.com
Stephanie Ascher Stern Investor Relations,
Inc.stephanie.ascher@sternir.com 212-362-1200
Media: Kaitlin GallagherBerry & Company Public
Relationskgallagher@berrypr.com212-253-8881
Fulcrum Therapeutics (NASDAQ:FULC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fulcrum Therapeutics (NASDAQ:FULC)
Historical Stock Chart
From Apr 2023 to Apr 2024